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Abstract  14 
Dendritic cells (DC) prime and orchestrate naïve T cell immunity in lymphoid 15 
organs, but recent data also highlight the importance of DC-effector T cell 16 
interactions in tissues.  These studies suggest that effector T cells require a 17 
second activating step in situ from tissue DCs in order to become fully 18 
competent for effector functions and/or proliferation and survival.  DC 19 
stimulation of effector T cells within tissues has evolved as a mechanism to 20 
ensure that T cells are activated to their full potential only at the site of ongoing 21 
infection.  Here we propose that under conditions of uncontrolled inflammation 22 
and release of tissue antigens, the same DC-dependent checkpoint 23 
perpetuates a destructive response and immunopathology.  24 
25 
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Control of effector T cell function in tissues – a role for DC? 26 
The immune system has evolved to ensure rapid and protective immunity 27 
against multiple pathogens while at the same time avoiding excessive 28 
damage to normal tissues. This careful balancing act requires exquisite 29 
control by multiple activating and regulatory checkpoints, many of which 30 
invoke the involvement of dendritic cells (DCs) that migrate to, or are resident 31 
within, secondary lymphoid organs.  In the steady state, DCs laden with self 32 
or harmless environmental antigens traffic at low rates to draining lymph 33 
nodes (LN).  Under these conditions, DC populations induce deletion of self-34 
reactive T cells or expansion of regulatory T cells (Treg) within the secondary 35 
lymphoid organs [1].  In contrast, during infection and exposure to pathogen-36 
associated molecular patterns, activated DC process microbial antigens 37 
within affected tissues and traffic to LN where they interact with naïve T cells, 38 
initiating a program of proliferation and effector T cell (Teff) differentiation [2].  39 
As the infection is cleared by the ensuing effector response, the number of 40 
antigen-loaded DCs that enter draining LN falls.  Furthermore, DC are killed 41 
by activated cytotoxic T lymphocytes (CTL) or their functions are modulated 42 
by naturally-occurring or inducible Treg, ensuring the primary response is self-43 
limiting [3-6].  While this process of induction and counter-regulation acts to 44 
avoid the priming of an excessive T cell response, there are several reasons 45 
to consider that additional levels of control are needed outside lymphoid 46 
organs.  For example, because there is a delay between DCs acquiring 47 
antigen in the infected tissue and initiation of naïve T cell activation, there 48 
exists the risk that effector cells armed with a full repertoire of harmful 49 
cytokines will induce an excessive response relative to the falling levels of 50 
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infection within the tissues due to activation of innate immune mechanisms.  51 
Conversely, Teff accessing tissues must also overcome multiple inhibitory 52 
influences, including exposure to co-inhibitory ligands (e.g. programmed 53 
death ligand (PD-L)-1) and suppression by peripheral tissue Treg before they 54 
can execute their functions [6].  In the absence of a mechanism to control the 55 
balance between effector and inhibitory responses, T cells recruited to the 56 
tissues may be unable to clear residual infection.  Thus, existing models that 57 
invoke the role of DCs solely within the afferent phase may lack the scope for 58 
fine-tuning the immune response according to precise levels of infection.  59 
Recent data highlighting the importance of DC-T cell interactions for effector 60 
function in tissues, suggests that DCs control an additional checkpoint in the 61 
efferent phase of the response.  Thus, DCs outside lymphoid organs may be 62 
required to shift the balance away from regulation and towards immunity, 63 
specifically at sites infected by pathogens.  In this way, DCs may also control 64 
Teff function, such that T cells only produce potentially damaging immune 65 
mediators in situations where the pathogen has not already been cleared by 66 
other immune responses.  In this Opinion we propose that this checkpoint 67 
becomes deregulated under conditions of inflammation and release of tissue 68 
antigens, and therefore that immunopathology in autoimmune disease or 69 
graft-versus-host disease (GVHD) is driven in situ by DCs that drive 70 
uncontrolled Teff activation in target organs.   71 
 72 
DCs at sites of infection and inflammation. 73 
The development of inducible murine models of DC ablation [7] or depletion 74 
of phagocytic cells such as monocytes by injection of clodronate-coated 75 
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liposomes [8] have enabled more precise definition of the role of DCs in vivo.  76 
In particular, the specific depletion of different DC populations at defined time 77 
points has allowed investigators to ask detailed questions about the role of 78 
DC-T cell interactions in situ in tissues.  In these systems, the cell type-79 
specific expression of a high affinity diphtheria toxin (DT) receptor (DTR) 80 
renders DCs exquisitely sensitive to killing by injection of DT [7].  81 
A prerequisite for any putative DC-specific checkpoint that activates Teff is 82 
that sufficient DC numbers are maintained in infected tissues.  Non-lymphoid 83 
DC populations have become increasingly well characterized, and can be 84 
defined in general by expression of the integrins CD11b and CD103 (for 85 
comprehensive reviews see [9, 10]).  According to the DC paradigm, DC 86 
activation is concomitant with migration out of the tissue to draining LN, and 87 
as such most DC research has focused on the role of DCs in lymphoid organs.  88 
However, significant numbers of DCs do remain in infected and/or inflamed 89 
tissue, and these cells may become refractory to subsequent activating 90 
trafficking stimuli, thus maintaining tissue DC numbers [11].  In addition, 91 
recruitment of DC precursors will rapidly replenish those activated DC 92 
populations exiting the tissues, with the outcome that inflamed tissues often 93 
contain higher numbers of DCs than in the steady state.  For example, 94 
CD11c+ DCs accumulate in Leishmania- and herpes simplex virus (HSV)-95 
infected skin [12, 13], and in the lungs of influenza-infected mice [14].  The 96 
majority of DCs recruited into inflamed or infected tissues are derived from 97 
Ly6Chigh monocytes, that have differentiated into CD11b+ DC-like cells [15, 98 
16].  These cells are rapidly recruited from the bone marrow in response to 99 
infection or inflammation [17], and provide a large supply of monocyte-100 
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derived, or inflammatory, DCs that may out-number other tissue-resident DCs 101 
[18] and dominate up-take of the infectious agent for T cell priming in draining 102 
LN [19].  Autoimmune diseases are often associated with an influx of large 103 
numbers of inflammatory DCs into the target tissue.  For example, DCs 104 
accumulate at the sites of intestinal inflammation in patients with inflammatory 105 
bowel diseases [20], and psoriatic skin contains a high frequency of 106 
inflammatory DCs [21].  These DCs may shape the local immune environment 107 
by the secretion of pro-inflammatory cytokines and chemokines [22, 23], and 108 
can directly cause tissue damage via production of the effector molecules 109 
TNF and iNOS (TipDC) [24].  However, the rapid recruitment of monocyte-110 
derived DC to inflamed tissues means that they may also become the 111 
dominant DC population to interact with incoming Teff in situ at the site of 112 
infection [9]. 113 
This shift to inflammatory DC populations may however not be true for all 114 
tissues.  For example, epidermal Langerhans cells (LCs) turn over very slowly 115 
with repopulation from a localized precursor population [10].  Unlike DCs in 116 
other tissues, LCs remain the dominant DC population in the inflamed 117 
epidermis [25], where local proliferation in situ may maintain cell numbers 118 
[26].  Indeed, monocytes are only recruited to the epidermis under conditions 119 
of severe inflammation and LC death, for example by UV-irradiation [10]. 120 
 121 
DC-T cell interactions at sites of infection. 122 
Teff home to diseased tissues, where they eliminate pathogens via direct 123 
killing of infected cells and through production of chemokines and cytokines, 124 
which recruit and activate immune defense mechanisms by other cells.  125 
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Studies over the last decade have demonstrated that Teff function is 126 
enhanced as they enter peripheral tissues, suggesting that interactions with 127 
tissue cells may be important in influencing the final repertoire of effector 128 
functions induced.  For example, influenza-specific Teff were found to 129 
undergo robust proliferation after entry into the lung [27]. Furthermore, 130 
adoptively transferred T cells that had been primed in vivo [28] or in vitro [29] 131 
were demonstrated to migrate to tissues and produce higher levels of effector 132 
cytokines than those that had trafficked to LN. Similarly, CD4+ T cells in the 133 
lungs of mice infected with Cryptococcus neoformans displayed a more 134 
activated phenotype, and produced more IFN, than those in draining LN [30].  135 
Until recently though, the precise involvement of DCs in this response had not 136 
been investigated. 137 
Depletion of DCs, or their precursors, after T cell priming exacerbates 138 
infection with influenza [31] or HSV-2 [18].  In the absence of antigen-139 
presenting DCs, pathogen (tetramer)-specific T cells do not proliferate and 140 
survive [31-33], or are not reactivated to produce IFN[18, 34], in order to 141 
mediate a protective response.  This interaction has been shown to be 142 
antigen-specific [31] and require co-stimulatory signals from DC in influenza-143 
infection models [33, 34].  CD11b+ inflammatory DCs, including Tip DCs, 144 
migrate into the lungs of influenza-infected mice [14, 35], where they present 145 
antigen to Teff [35], and are therefore strong candidates to activate the 146 
protective T cell response in this model.  Monocyte-derived DCs were also 147 
characterized as the DC population which induced IFN-production by 148 
recruited T cells in HSV-2-infected mice [18].  These reports have suggested 149 
that antigen-specific interactions between tissue DCs and T cells are required 150 
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to activate full Teff function at the site of infection.  However, in these studies, 151 
interactions between Teff and different populations of tissue DCs was inferred 152 
using ex vivo DC-restimulation assays [18], or add-back of specific DC 153 
populations to DC-depleted mice [31], which do not necessarily reflect the 154 
cellular interactions which occur in vivo.  Notably, DC populations distinct from 155 
the alveolar DC subset that were depleted by treatment with clodronate 156 
liposomes, were required to rescue Teff function [31].  Three further studies 157 
have investigated the outcome of the interaction between DCs and effector T 158 
cells at the site of inflammation, either by directly analyzing T cell cytokine 159 
production ex vivo without restimulation by DCs, or using multi-photon 160 
imaging to track Teff in real time.  Depletion of DTR-expressing DCs by 161 
injection of DT was used to show that DCs in the dermis of mice that had been 162 
immunized with protein and adjuvant, or in the lungs of influenza-infected 163 
mice, were required to induce antigen-specific IFN production by T cells 164 
recruited to the inflamed/infected sites [34, 36].  CD11b+ DCs were also 165 
recruited into the central nervous system (CNS) of lymphocytic chorio-166 
meningitis virus (LCMV)-infected mice, where they formed stable long-lived 167 
contacts with incoming T cells.  These interactions resulted in the proliferation 168 
of Teff in situ in the meninges [37].  Collectively, these studies demonstrate 169 
that DC-T cell interactions in tissues enhance T cell function.  The research 170 
to date has either focused on investigating the direct augmentation of T cell 171 
cytokine production by DCs at a single cell level, or the indirect enhancement 172 
of Teff function due to proliferation in situ at the infection site.  New studies 173 
are required to directly compare whether both scenarios occur within an 174 
infected tissue, or whether the interaction with DCs outside lymphoid organs 175 
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has different effects on Teff function, perhaps depending on the local 176 
environment and the signals delivered by activating DCs.  It has been 177 
postulated that tissue antigen presenting cell (APC)-T cell interactions take 178 
place within discrete areas of inflamed or infected tissues, that may facilitate 179 
rapid activation of effector memory T cells upon secondary infection [38, 39].  180 
These sites include tertiary lymphoid structures such as those found in the 181 
lung, which are required for the maintenance of chronic immunity [40].  182 
However, whether discrete regions within the tissue are required to foster 183 
interactions between Teff and DCs has not been carefully addressed. 184 
 185 
Do DC- Teff interactions perpetuate disease? 186 
During the development of autoimmune disease, tissue-resident DCs will 187 
migrate to draining LN to initiate the primary response.  Priming is perpetuated 188 
as incoming inflammatory DCs subsequently acquire tissue antigens released 189 
by auto-reactive CTL, and migrate in turn to draining LN [41, 42].  In 190 
experimental models of autoimmunity however, depletion of DCs ameliorates 191 
tissue destruction independently of T cell priming [25, 43, 44].  Thus, DTR 192 
models of DC/LC depletion have been used to show that activated CD4+ T 193 
cells interact with kidney DCs to produce cytokines in situ and recruit 194 
autoreactive CTL [43], while CD8+ T cells are activated to enhance effector 195 
function, and therefore tissue damage, by epidermal LCs [25].  In the 196 
MRL.Fas mouse model of systemic lupus erythematosus DC were recently 197 
shown to be required for the proliferation of, and increased IFN-production 198 
by, Teff in LN, and tissue immunopathology was less severe in the constitutive 199 
absence of DCs [44].  However, interactions between DC and Teff in 200 
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peripheral tissues were not addressed in this study.  Within the CNS, and in 201 
accord with the LCMV study already discussed [37], MHC II+ APC form long-202 
lasting contacts with Teff that were in the process of crossing pial vascular 203 
walls [45].  In this elegant study, which exploited cytofluorometry to directly 204 
analyze effector cytokine production at the single cell level by parenchymal T 205 
cells in situ, it was found that APC-T cell interactions result in the activation 206 
of pro-inflammatory cytokines, chemokines and metalloproteases which 207 
facilitated entry of CTL deep into the CNS parenchyma to cause clinical 208 
disease [45].  Taken together, these studies implicate DC-Teff interactions in 209 
murine models of autoimmunity. 210 
It was also recently demonstrated that resident rather than recruited DC can 211 
license Teff under certain conditions.  This conclusion was derived from 212 
experiments dissecting the mechanism of cutaneous injury induced by 213 
allogenic T cells following bone marrow transplant.  Using a tractable model 214 
of cutaneous GVHD, in which inflammation is induced by topical application 215 
of a Toll-like receptor agonist, and depletion of LC from Langerin-DTR 216 
recipients, it was found that tissue injury was reduced in the absence of LC, 217 
despite recruitment of CTL into the epidermis [25].  Although primed Teff were 218 
cytotoxic against hemtopoietic cells, they required the presence of epidermal 219 
host LC to up-regulate transcription of effector molecules once in the 220 
epidermis [25].  These data suggest that LCs can also control the Teff function 221 
under certain conditions.  However, LCs were not required for this step in 222 
models of dermatitis or subcutaneous vaccination, where CD11b+ DCs were 223 
the major protagonists.  Therefore, a key question for future studies is to 224 
determine whether licensing is a ‘default’ mechanism of any DC population 225 
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that is within a tissue at the time of Teff infiltration or a unique property of 226 
individual subsets. 227 
 228 
Concluding remarks. 229 
Recent data highlight the importance of DC-T cell interactions in tissues to 230 
enhance protective immunity against infection.  We propose that Teff are 231 
licensed by DCs in situ, and that this step provides an important checkpoint 232 
to activate maximal effector function at sites of infection.  DCs may be 233 
licensed by interaction with pathogen-derived molecules [46], or CD4 T cells 234 
[47] and as a result persist in an altered state that is equipped to activate 235 
effector T cell responses.  Here, we suggest that DCs may themselves 236 
license, and therefore modulate, CD4+ and CD8+ Teff function.  In this context, 237 
the term licensing describes an interaction between tissue DCs and recruited 238 
T cells that leads to enhanced Teff function.  This may be due to a 239 
combination of augmented production of effector cytokines, chemokines and 240 
other molecules, and/or local expansion of Teff due to enhanced proliferation 241 
and/or survival.  Under conditions of inflammation and release of tissue 242 
antigens, this checkpoint could result in the aggravation of a dysregulated T 243 
cell response, whereby DCs drive the continued proliferation and activation of 244 
tissue-destructive T cells (Figure 1).  During immune responses to pathogens 245 
the licensing of Teff by DCs will be limited over time as fewer T cells are 246 
primed in draining LN, and pathogen-derived antigens are cleared from the 247 
tissue.  At this point tissue-specific regulatory mechanisms such as exposure 248 
to PD-L1, and suppression by Treg will dominate immune responses in the 249 
tissue to ensure that any autoreactive T cells activated during the anti-250 
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pathogen response are not licensed by DC at the infected site.  In addition, 251 
DC may also directly license Treg function [36].  However, during 252 
autoimmunity these immunosuppressive responses are often impaired, for 253 
example due to inhibition of Treg function [48].  In this context the unchecked 254 
augmentation of self-reactive Teff function by DC will further drive T cell-255 
mediated immunopathology.   256 
 257 
Despite differences reported in the literature on the effects that this licensing 258 
step has on Teff function, a consensus is emerging on the nature of the DC 259 
that mediates this response.  Thus, recruited inflammatory (CD11b+) DCs 260 
license enhanced Teff function in both infection and immunopathology (Figure 261 
1).  This is in accord with a role for these DCs during the effector phase of the 262 
immune response, as recently suggested by others [9].  Many questions 263 
remain about the nature of the interaction between DCs and Teff in tissues; 264 
for example, more work is needed to understand to what extent MHC-T cell 265 
receptor signaling alone is sufficient to activate enhanced effector proliferation 266 
and/or function, and how different co-stimulatory or -inhibitory signals from 267 
DC control Teff function [33, 34].  In addition, it is not known whether DCs 268 
must be activated to license incoming T cells.  DCs require pathogen-derived 269 
signals in order to prime a naïve T cell response [49].  However, Teff will 270 
potentially have different requirements, and inflammatory cytokine-driven 271 
activation of tissue DCs may be sufficient for them to interact with, and 272 
license, recruited T cells.  More data is also needed to determine whether this 273 
DC-dependent licensing step is specific for the primary response, or if it is 274 
also required to re-stimulate memory T cells on secondary challenge by 275 
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pathogens (see Box 1).  Dermal DCs have been shown to license cytokine 276 
production by Treg in the skin [36] and an interesting possibility is that DCs 277 
control the balance between effector and regulatory function in situ at the site 278 
of infection.  Understanding and targeting DC-licensing of T cells beyond 279 
lymphoid organs may represent an important therapeutic step to both 280 
enhance the function of pathogen- and tumor-specific T cells in situ, and limit 281 
T cell-mediated pathology in autoimmunity and GVHD. 282 
283 
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Legend 427 
Figure 1.  Licensing of effector T cell function by tissue DCs 428 
A.  Following infection, monocytes will be rapidly recruited from the blood into 429 
the infected tissue.  Monocytes will differentiate into inflammatory DCs that 430 
present infection-derived antigen to incoming effector T cells.  This interaction 431 
will result in proliferation and/or enhanced effector cytokine production by T 432 
cells, ensuring that a sufficient T cell response is elicited to clear the infection.  433 
Depletion of priming DCs and therefore effector T cells in draining LN, and a 434 
reduction in the amount of pathogen-derived antigen present at the infected 435 
site due to clearance of the invading organism, will limit the duration of the 436 
response, with minimal damage to the surrounding tissue by Teff. 437 
B.  During the development of autoimmune disease, inflammatory DCs which 438 
have been recruited to the inflamed tissue, will present self antigens to Teff. 439 
This interaction will enhance effector function, leading to immunopathology 440 
as autoreactive T cells attack cells in the surrounding tissue, and may also 441 
produce chemokines and proteases to invade further into the tissue.  442 
Continual recruitment of licensing DCs presenting tissue-derived antigen, and 443 
therefore the persistent enhancement of T cell function perpetuates the cycle, 444 
resulting in severe immunopathology in the target organ. 445 
446 
 20 
Box 1 447 
Activation of memory T cells by tissue DCs. 448 
Memory T cells can be divided into two populations, central memory T cells 449 
(TCM) that reside in LN, and effector memory T cells (TEM) that circulate 450 
through tissues, and are poised to react to secondary infections.  DCs are 451 
required to reactivate memory T cells after viral infection [50], and specific DC 452 
populations may perform this function [51].  In parallel with the primary 453 
response, a DC-dependent checkpoint could be important to activate TEM 454 
function only in those tissues exposed to secondary challenge by a pathogen.  455 
Nonetheless, it is not known whether memory T cells that have interacted with 456 
tissue DCs are more functionally active than those that have seen antigen on 457 
other cells.  Inflammatory DCs activated local proliferation of memory T cells 458 
in response to HSV-1 infection [52], and both B cells and DCs (though not 459 
monocyte-derived DCs) were also required to activate CD4+ memory T cells 460 
in a mucosal model of HSV-2 [18, 53].  Using a murine model of postoperative 461 
ileus induced by surgical manipulation of the intestine, and DT-mediated 462 
depletion of DTR+ DC, it was recently shown that CD11b+ CD103+ DC 463 
recruited into the inflamed tissue were required for differentiation of T helper 464 
1-like memory T cells, and therefore drove the postoperative inflammatory 465 
response [54].  More studies are still needed however to determine whether 466 
tissue DCs specifically enhance memory T cell function upon restimulation 467 
outside lymphoid organs, and whether the licensing DCs populations are the 468 
same as those required during the primary response. 469 
